Why Many Global Drugs Never Reach Japan
Despite faster reviews, many global drugs never reach Japan. Learn how early development decisions, trial…
CertaraFebruary 5, 2026
Trial Designs: Non-inferiority vs. Superiority vs. Equivalence
Understand superiority, non-inferiority, and equivalence trials, how their hypotheses differ, and how trial design impacts…
CertaraFebruary 3, 2026
Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants
This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…
CertaraFebruary 2, 2026
Modeling Population PK with Power, Speed, and Ease-of-Use (Phoenix® NLME & Pirana®)
Discover population PK modeling made faster and easier with Phoenix NLME and Pirana in this…
CertaraJanuary 30, 2026
Regulatory-Trusted Software for Smarter PK/PD Workflows (Phoenix WinNonlin®)
This on demand session demonstrates how Phoenix WinNonlin® and other tools work together within Phoenix®…
CertaraJanuary 27, 2026
How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most
Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…
CertaraJanuary 26, 2026
